## The headline miss is real — and it forces a reset in the near-term narrative Gossamer disclosed that in its Phase 3 PROSERA trial (seralutinib in PAH), the drug **did not clear the prespecified statistical bar for the primary endpoint**: the placebo-adjusted Hodges‑Lehmann treatment effect on 6-minute walk distance (6MWD) at Week 24 was **+13.3 meters** with **p = 0.0320**, which **missed the trial’s α = 0.025 threshold**. ["did not meet the prespecified threshold"](0001728117-26-000004|0) ["Hodges‑Lehmann treatment effect was +13.3 meters"](0001728117-26-000004|0) ["p‑value of 0.0320"](0001728117-26-000004|0) ["(α = 0.025)"](0001728117-26-000004|0) That single line matters because it constrains how the full dataset can be “counted” in a registrational argument: management explicitly noted that **key secondary endpoints cannot be evaluated for statistical significance** as a result. ["cannot be evaluated for statistical significance"](0001728117-26-000004|0) ## “Engage FDA” + “pause enrollment” = the company is signaling a binary decision point, not business-as-usual The filing is direct that the company **expects to meet with the U.S. FDA to discuss the path forward** for seralutinib in PAH. ["expects to meet with the U.S. FDA"](0001728117-26-000004|0) ["discuss the path forward"](0001728117-26-000004|0) More importantly “between the lines,” Gossamer also disclosed it is **pausing enrollment in SERANATA** specifically to evaluate PROSERA’s implications (calling out **regional discrepancies in placebo response**). That’s a meaningful escalation: pausing an active Phase 3 program is typically what you do when you are re-underwriting probability-of-success and capital allocation in real time. ["pausing enrollment into the SERANATA Study"](0001728117-26-000004|0) ["particularly regional discrepancies in placebo response"](0001728117-26-000004|0) ## The “hidden alpha” is that the dataset wasn’t uniformly negative — it hints at a severity-enriched signal (if regulators buy it) Even while acknowledging the primary endpoint miss, Gossamer disclosed that **all four key secondary endpoints favored seralutinib vs placebo in the overall population** (nominally). That’s not approval-ready on its own, but it can matter in FDA discussions when paired with a coherent explanation for the primary endpoint shortfall. ["All four key secondary endpoints favored seralutinib versus placebo"](0001728117-26-000004|0) The investor deck attached to the same 8‑K sharpens the “severity-enriched” angle: in a **prespecified intermediate-/high-risk subgroup (REVEAL Lite 2 ≥ 6)**, the Week 24 primary analysis shows a **Hodges‑Lehmann location shift of 19.975m** with **p = 0.0207 (nominal)**, while the low-risk subgroup shows a much smaller effect (4.548m; p = 0.5561, nominal). ["Intermediate-to-High Risk"](0001728117-26-000004|1) ["H‑L Location Shift: 19.975m"](0001728117-26-000004|1) ["p-value: 0.0207"](0001728117-26-000004|1) ["H‑L Location Shift: 4.548m"](0001728117-26-000004|1) ["p-value: 0.5561"](0001728117-26-000004|1) If the FDA is open to (a) a refined label strategy, (b) an additional confirmatory study in a severity-enriched population, or (c) an endpoint framework less exposed to placebo inflation, this subgroup behavior is likely the core “option value” management is trying to preserve. ## Placebo inflation and regional dispersion look like the real culprits — and management is explicitly building that case The company’s own disclosure frames the “why” behind the miss: **regional discrepancies in placebo response** were called out as a central issue, and the SERANATA pause is explicitly tied to evaluating that impact. ["regional discrepancies in placebo response"](0001728117-26-000004|0) ["pausing enrollment"](0001728117-26-000004|0) The deck goes one step further and states placebo effect was **more pronounced in certain regions**, “particularly Latin America & Asia/Middle East.” ["Placebo Effect was More Pronounced"](0001728117-26-000004|1) ["particularly Latin America & Asia/Middle East"](0001728117-26-000004|1) This is the subtext investors should focus on: management is not treating PROSERA as “drug didn’t work,” but as “trial signal masked by an unusually strong/uneven placebo response,” which is exactly the type of narrative that can keep a program alive in some form after a statistical miss. ## Safety/tolerability: not catastrophic, but there are two watch-items that can shape risk-benefit Gossamer disclosed seralutinib was “generally well tolerated,” but also quantified two notable liabilities: **cough (37.0%)** and **transaminase elevations ≥3× ULN (13% vs 1% placebo)**. ["cough, reported in 37.0%"](0001728117-26-000004|0) ["Transaminase elevations"](0001728117-26-000004|0) ["13% of patients"](0001728117-26-000004|0) ["1% of patients receiving placebo"](0001728117-26-000004|0) Those don’t automatically kill a PAH asset—especially in a heavily pretreated population—but they can influence (1) what subgroup is viable, (2) whether a benefit must be larger to justify risk, and (3) how FDA frames any “path forward.” ## Near-term catalyst investors may be underweighting: CT-FRI readout as an attempted “mechanism-of-benefit” bridge The 8‑K also flags that results from a **CT functional respiratory imaging (FRI) substudy** are expected “in the coming weeks,” and are expected to provide further insight into treatment effect (including pulmonary blood volume distribution). That’s a tell: management is likely looking for mechanistic evidence to support a re-interpretation of the clinical endpoints and/or to rationalize a redesigned trial. ["CT functional respiratory imaging (FRI) substudy"](0001728117-26-000004|0) ["expected in the coming weeks"](0001728117-26-000004|0) ["pulmonary blood volume distribution"](0001728117-26-000004|0) **Bottom line:** The latest disclosures frame PROSERA less as a clean failure and more as a **statistical miss with pockets of signal + a placebo/geography problem**, which creates a narrower—but still potentially monetizable—regulatory and strategic option set. ["did not meet the prespecified threshold"](0001728117-26-000004|0) ["favored seralutinib"](0001728117-26-000004|0) ["regional discrepancies"](0001728117-26-000004|0)

## The headline miss is real — and it forces a reset in the near-term narrative Gossamer disclosed that in its Phase 3 PROSERA trial (seralutinib in PAH), the drug **did not clear the prespecified statistical bar for the primary endpoint**: the placebo-adjusted Hodges‑Lehmann treatment effect on 6-minute walk distance (6MWD) at Week 24 was **+13.3 meters** with **p = 0.0320**, which **missed the trial’s α = 0.025 threshold**. ["did not meet the prespecified threshold"](0001728117-26-000004|0) ["Hodges‑Lehmann treatment effect was +13.3 meters"](0001728117-26-000004|0) ["p‑value of 0.0320"](0001728117-26-000004|0) ["(α = 0.025)"](0001728117-26-000004|0) That single line matters because it constrains how the full dataset can be “counted” in a registrational argument: management explicitly noted that **key secondary endpoints cannot be evaluated for statistical significance** as a result. ["cannot be evaluated for statistical significance"](0001728117-26-000004|0) ## “Engage FDA” + “pause enrollment” = the company is signaling a binary decision point, not business-as-usual The filing is direct that the company **expects to meet with the U.S. FDA to discuss the path forward** for seralutinib in PAH. ["expects to meet with the U.S. FDA"](0001728117-26-000004|0) ["discuss the path forward"](0001728117-26-000004|0) More importantly “between the lines,” Gossamer also disclosed it is **pausing enrollment in SERANATA** specifically to evaluate PROSERA’s implications (calling out **regional discrepancies in placebo response**). That’s a meaningful escalation: pausing an active Phase 3 program is typically what you do when you are re-underwriting probability-of-success and capital allocation in real time. ["pausing enrollment into the SERANATA Study"](0001728117-26-000004|0) ["particularly regional discrepancies in placebo response"](0001728117-26-000004|0) ## The “hidden alpha” is that the dataset wasn’t uniformly negative — it hints at a severity-enriched signal (if regulators buy it) Even while acknowledging the primary endpoint miss, Gossamer disclosed that **all four key secondary endpoints favored seralutinib vs placebo in the overall population** (nominally). That’s not approval-ready on its own, but it can matter in FDA discussions when paired with a coherent explanation for the primary endpoint shortfall. ["All four key secondary endpoints favored seralutinib versus placebo"](0001728117-26-000004|0) The investor deck attached to the same 8‑K sharpens the “severity-enriched” angle: in a **prespecified intermediate-/high-risk subgroup (REVEAL Lite 2 ≥ 6)**, the Week 24 primary analysis shows a **Hodges‑Lehmann location shift of 19.975m** with **p = 0.0207 (nominal)**, while the low-risk subgroup shows a much smaller effect (4.548m; p = 0.5561, nominal). ["Intermediate-to-High Risk"](0001728117-26-000004|1) ["H‑L Location Shift: 19.975m"](0001728117-26-000004|1) ["p-value: 0.0207"](0001728117-26-000004|1) ["H‑L Location Shift: 4.548m"](0001728117-26-000004|1) ["p-value: 0.5561"](0001728117-26-000004|1) If the FDA is open to (a) a refined label strategy, (b) an additional confirmatory study in a severity-enriched population, or (c) an endpoint framework less exposed to placebo inflation, this subgroup behavior is likely the core “option value” management is trying to preserve. ## Placebo inflation and regional dispersion look like the real culprits — and management is explicitly building that case The company’s own disclosure frames the “why” behind the miss: **regional discrepancies in placebo response** were called out as a central issue, and the SERANATA pause is explicitly tied to evaluating that impact. ["regional discrepancies in placebo response"](0001728117-26-000004|0) ["pausing enrollment"](0001728117-26-000004|0) The deck goes one step further and states placebo effect was **more pronounced in certain regions**, “particularly Latin America & Asia/Middle East.” ["Placebo Effect was More Pronounced"](0001728117-26-000004|1) ["particularly Latin America & Asia/Middle East"](0001728117-26-000004|1) This is the subtext investors should focus on: management is not treating PROSERA as “drug didn’t work,” but as “trial signal masked by an unusually strong/uneven placebo response,” which is exactly the type of narrative that can keep a program alive in some form after a statistical miss. ## Safety/tolerability: not catastrophic, but there are two watch-items that can shape risk-benefit Gossamer disclosed seralutinib was “generally well tolerated,” but also quantified two notable liabilities: **cough (37.0%)** and **transaminase elevations ≥3× ULN (13% vs 1% placebo)**. ["cough, reported in 37.0%"](0001728117-26-000004|0) ["Transaminase elevations"](0001728117-26-000004|0) ["13% of patients"](0001728117-26-000004|0) ["1% of patients receiving placebo"](0001728117-26-000004|0) Those don’t automatically kill a PAH asset—especially in a heavily pretreated population—but they can influence (1) what subgroup is viable, (2) whether a benefit must be larger to justify risk, and (3) how FDA frames any “path forward.” ## Near-term catalyst investors may be underweighting: CT-FRI readout as an attempted “mechanism-of-benefit” bridge The 8‑K also flags that results from a **CT functional respiratory imaging (FRI) substudy** are expected “in the coming weeks,” and are expected to provide further insight into treatment effect (including pulmonary blood volume distribution). That’s a tell: management is likely looking for mechanistic evidence to support a re-interpretation of the clinical endpoints and/or to rationalize a redesigned trial. ["CT functional respiratory imaging (FRI) substudy"](0001728117-26-000004|0) ["expected in the coming weeks"](0001728117-26-000004|0) ["pulmonary blood volume distribution"](0001728117-26-000004|0) **Bottom line:** The latest disclosures frame PROSERA less as a clean failure and more as a **statistical miss with pockets of signal + a placebo/geography problem**, which creates a narrower—but still potentially monetizable—regulatory and strategic option set. ["did not meet the prespecified threshold"](0001728117-26-000004|0) ["favored seralutinib"](0001728117-26-000004|0) ["regional discrepancies"](0001728117-26-000004|0)